Phaseline

Companies › Zhejiang Hanmai Pharmaceutical Technology

Zhejiang Hanmai Pharmaceutical Technology: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Neurology, Metabolic and endocrine; next expected readout Aug 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
YJ001 for Spray Use–Phase 3Diabetic Peripheral Neuropathic Pain (DPNP); Diabetic Peripheral Neuropathic PainAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06361108YJ001 for Spray UsePhase 1Diabetic Peripheral Neuropathic PainMetabolic and endocrineDec 2025
NCT07859111YJ001 for Spray UsePhase 3Diabetic Peripheral Neuropathic Pain (DPNP)NeurologyAug 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

IntraBio Upsher-Smith Laboratories Urovant Sciences Shenzhen Wingor Biotechnology NeuroBiogen

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.